A preclinical model of THC edibles that produces high-dose cannabimimetic responses
暂无分享,去创建一个
M. Bruchas | N. Stella | A. Torrens | Dennis Sarroza | Anthony English | Fleur Uittenbogaard | Anna Slaven | Danielle Piomelli | Benjamin Land
[1] G. Schauer,et al. Cannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators , 2022, Journal of Cannabis Research.
[2] C. D. Fowler,et al. Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats , 2021, Psychopharmacology.
[3] S. Anagnostaras,et al. Quantifying the Acoustic Startle Response in Mice Using Standard Digital Video , 2020, Frontiers in Behavioral Neuroscience.
[4] A. Das,et al. Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice , 2020, The Journal of Pharmacology and Experimental Therapeutics.
[5] Cedric E. Ginestet,et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis , 2020, The lancet. Psychiatry.
[6] K. Mackie,et al. Self-administration of edible Δ9-tetrahydrocannabinol and associated behavioral effects in mice. , 2019, Drug and alcohol dependence.
[7] J. Clark,et al. Voluntary oral consumption of Δ9-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood , 2019, Neuropsychopharmacology.
[8] D. Hasin,et al. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings , 2019, The American journal of drug and alcohol abuse.
[9] Zeena M. G. Rivera,et al. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain , 2019, bioRxiv.
[10] S. Boehm,et al. Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent , 2019, Front. Behav. Neurosci..
[11] C. Morgan,et al. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function , 2018, Translational Psychiatry.
[12] J. Wiley,et al. Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats , 2018, Neuropharmacology.
[13] I. Ibarra-Lecue,et al. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway , 2018, Neuropsychopharmacology.
[14] F. Barrett,et al. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs , 2018, Cannabis and cannabinoid research.
[15] P. Piazza,et al. Cannabinoid‐Induced Tetrad in Mice , 2017, Current protocols in neuroscience.
[16] Christopher M. Jones,et al. Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. , 2016, The lancet. Psychiatry.
[17] R. Dinis-Oliveira. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity , 2016, Drug metabolism reviews.
[18] N. Ginovart,et al. Repeated but not acute treatment with ∆9-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: Reversal by the dopamine D2/3 receptor antagonist haloperidol , 2014, European Neuropsychopharmacology.
[19] J. Clark,et al. Chronic alcohol intake during adolescence, but not adulthood, promotes persistent deficits in risk-based decision making. , 2014, Alcoholism, clinical and experimental research.
[20] P. McGuire,et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. , 2012, Current pharmaceutical design.
[21] Raquel E Gur,et al. Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. , 2012, Neuropsychology.
[22] B. Platt,et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour , 2011, Psychopharmacology.
[23] D. Dow-Edwards,et al. Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat. , 2010, Neurotoxicology and teratology.
[24] I. McGregor,et al. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. , 2010, The international journal of neuropsychopharmacology.
[25] D. Selley,et al. FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration , 2010, Neuropsychopharmacology.
[26] R. Maldonado,et al. Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test , 2009, Psychopharmacology.
[27] A F Cohen,et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans , 2008, Journal of psychopharmacology.
[28] W. A. Wilson,et al. Sex differences in the effects of Δ9-tetrahydrocannabinol on spatial learning in adolescent and adult rats , 2007, Behavioural pharmacology.
[29] S. Puglisi‐Allegra,et al. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli , 2007, Proceedings of the National Academy of Sciences.
[30] Y. Shoyama,et al. Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice , 2006, Pharmacology Biochemistry and Behavior.
[31] A. Lichtman,et al. Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[32] K. Norén,et al. Determination of Δ1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography–mass spectrometry , 1989 .
[33] J. Scimeca,et al. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. , 1987, The Journal of pharmacology and experimental therapeutics.
[34] L. Hollister,et al. Delta‐8‐ and delta‐9‐tetrahydrocannabinol; Comparison in man by oral and intravenous administration , 1973, Clinical pharmacology and therapeutics.
[35] J. Axelrod,et al. Delta-9-Tetrahydrocannabinol: Localization in Body Fat , 1973, Science.
[36] L. Hollister,et al. Tetrahydrocannabinol Isomers and Homologues: Contrasted Effects of Smoking , 1970, Nature.
[37] J. Jaffe,et al. 1-δ9-Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse , 1969, Science.